CLSD
Clearside Biomedical, Inc. [CLSD] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
CLSD Stock Summary
Top 10 Correlated ETFs
CLSD
Top 10 Correlated Stocks
CLSD
In the News
CLSD Financial details
Company Rating
Sell
Market Cap
93.4M
Income
-36.33M
Revenue
8.23M
Book val./share
-0.25
Cash/share
0.46
Dividend
-
Dividend %
-
Employees
30
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-2.18
Forward P/E
-
PEG
-7.14
P/S
39.8
P/B
-6.8
P/C
2.76
P/FCF
-3.39
Quick Ratio
5.09
Current Ratio
5.28
Debt / Equity
-2.66
LT Debt / Equity
-2.64
-
-
EPS (TTM)
-0.59
EPS next Y
-
EPS next Q
-
EPS this Y
-7.02%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-7.9%
Revenue last 5Y
30.5%
Revenue Q/Q
638.65%
EPS Q/Q
-48.4%
-
-
-
-
SMA20
-50%
SMA50
-
SMA100
-
Inst Own
11.46%
Inst Trans
0.82%
ROA
-116%
ROE
3551%
ROC
-1.05%
Gross Margin
75%
Oper. Margin
-1357%
Profit Margin
-1813%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.65-2.12
52W High
-
52W Low
-
RSI
45
Rel Volume
0.54
Avg Volume
362.29K
Volume
194.72K
Perf Week
-2.31%
Perf Month
-23.95%
Perf Quarter
81.17%
Perf Half Y
47.61%
-
-
-
-
Beta
2.326
-
-
Volatility
0.05%, 0.21%
Prev Close
-3.79%
Price
1.27
Change
-0.78%
CLSD Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.06 | 0.17 | 0.51 | 0.02 | 0.13 | |
| Net income per share | -0.8 | -0.39 | 0.01 | -0.57 | -0.53 | |
| Operating cash flow per share | -0.71 | -0.28 | -0.18 | -0.22 | -0.29 | |
| Free cash flow per share | -0.71 | -0.28 | -0.18 | -0.23 | -0.32 | |
| Cash per share | 0.59 | 0.37 | 0.52 | 0.8 | 0.47 | |
| Book value per share | 0.29 | 0.19 | 0.65 | 0.18 | -0.26 | |
| Tangible book value per share | 0.29 | 0.19 | 0.65 | 0.18 | -0.26 | |
| Share holders equity per share | 0.29 | 0.19 | 0.65 | 0.18 | -0.26 | |
| Interest debt per share | 0.19 | 0.05 | 0.01 | 0.08 | 0.84 | |
| Market cap | 110.7M | 127.43M | 160.85M | 67.43M | 72.31M | |
| Enterprise value | 94.51M | 112.12M | 131.09M | 20.46M | 86.4M | |
| P/E ratio | -3.62 | -7.07 | 427.8 | -1.98 | -2.23 | |
| Price to sales ratio | 50.94 | 16.14 | 5.44 | 50.81 | 8.79 | |
| POCF ratio | -4.09 | -9.71 | -14.99 | -5.05 | -3.99 | |
| PFCF ratio | -4.09 | -9.67 | -14.99 | -4.95 | -3.63 | |
| P/B Ratio | 9.92 | 14.54 | 4.24 | 6.36 | -4.54 | |
| PTB ratio | 9.92 | 14.54 | 4.24 | 6.36 | -4.54 | |
| EV to sales | 43.49 | 14.2 | 4.43 | 15.42 | 10.5 | |
| Enterprise value over EBITDA | -3.12 | -6.25 | -291.96 | -0.69 | -3.49 | |
| EV to operating cash flow | -3.49 | -8.55 | -12.21 | -1.53 | -4.76 | |
| EV to free cash flow | -3.49 | -8.51 | -12.21 | -1.5 | -4.34 | |
| Earnings yield | -0.28 | -0.14 | 0 | -0.51 | -0.45 | |
| Free cash flow yield | -0.24 | -0.1 | -0.07 | -0.2 | -0.28 | |
| Debt to equity | 0.57 | 0.23 | 0.02 | 0.12 | -2.66 | |
| Debt to assets | 0.24 | 0.1 | 0.02 | 0.03 | 1.24 | |
| Net debt to EBITDA | 0.53 | 0.85 | 66.28 | 1.59 | -0.57 | |
| Current ratio | 2.31 | 1.82 | 9.08 | 8.34 | 4.42 | |
| Interest coverage | -29.31 | -53.54 | 0 | -9.07 | -2.65 | |
| Income quality | 0.88 | 0.72 | -28.55 | 0.41 | 0.56 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 7.74 | 1.36 | 0.39 | 8.87 | 1.44 | |
| Research and developement to revenue | 7.21 | 1.91 | 0.63 | 14.79 | 2.53 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0.02 | 0.1 | |
| Capex to revenue | -0.01 | -0.01 | 0 | -0.19 | -0.22 | |
| Capex to depreciation | -0.12 | -0.31 | 0 | -1.7 | -26.52 | |
| Stock based compensation to revenue | 2.12 | 0.46 | 0.17 | 3.68 | 0.51 | |
| Graham number | 2.29 | 1.28 | 0.31 | 1.5 | 1.74 | |
| ROIC | -1.6 | -1.51 | -0.02 | -2.38 | -0.92 | |
| Return on tangible assets | -1.14 | -0.93 | 0.01 | -0.66 | -0.95 | |
| Graham Net | 0.18 | 0.14 | 0.57 | 0.13 | -0.34 | |
| Working capital | 14.32M | 8.18M | 37.5M | 42.48M | 23.31M | |
| Tangible asset value | 11.16M | 8.76M | 37.98M | 10.61M | -15.91M | |
| Net current asset value | 9.6M | 7.56M | 37.21M | 7.56M | -19.81M | |
| Invested capital | 0.57 | 0.23 | 0.02 | 0.12 | -2.66 | |
| Average receivables | 0 | 0 | 5M | 5M | 85K | |
| Average payables | 4.07M | 1.64M | 1.47M | 995.5K | 1.63M | |
| Average inventory | 0 | 0 | 460.5K | 460.5K | 0 | |
| Days sales outstanding | 0 | 0 | 123.42 | 0 | 7.54 | |
| Days payables outstanding | 0 | 0 | 1.93K | 1.88K | 1.91K | |
| Days of inventory on hand | 0 | 0 | 1.89K | 0 | 0 | |
| Receivables turnover | 0 | 0 | 2.96 | 0 | 48.39 | |
| Payables turnover | 0 | 0 | 0.19 | 0.19 | 0.19 | |
| Inventory turnover | 0 | 0 | 0.19 | 0 | 0 | |
| ROE | -2.74 | -2.06 | 0.01 | -3.21 | 2.04 | |
| Capex per share | 0 | 0 | 0 | 0 | -0.03 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.01 | 0 | 0.02 | 0.01 | 0.1 | |
| Net income per share | -0.14 | -0.21 | -0.15 | -0.15 | -0.08 | |
| Operating cash flow per share | -0.09 | -0.12 | -0.09 | -0.1 | 0.01 | |
| Free cash flow per share | -0.09 | -0.12 | -0.1 | -0.11 | 0.01 | |
| Cash per share | 0.8 | 0.68 | 0.57 | 0.46 | 0.46 | |
| Book value per share | 0.18 | 0.04 | -0.08 | -0.21 | -0.25 | |
| Tangible book value per share | 0.18 | 0.04 | -0.08 | -0.21 | -0.25 | |
| Share holders equity per share | 0.18 | 0.04 | -0.08 | -0.21 | -0.25 | |
| Interest debt per share | 0.06 | 0.06 | 0.06 | -0.02 | 0.72 | |
| Market cap | 67.66M | 63.62M | 69.05M | 53.92M | 73.01M | |
| Enterprise value | 20.69M | 23.42M | 35.2M | 26.2M | 87.09M | |
| P/E ratio | -1.97 | -1.21 | -1.9 | -1.45 | -3.78 | |
| Price to sales ratio | 205.04 | 15.9K | 67.83 | 62.77 | 11.51 | |
| POCF ratio | -12.07 | -8.82 | -12.93 | -8.88 | 147.5 | |
| PFCF ratio | -11.87 | -8.68 | -10.73 | -8.27 | 194.7 | |
| P/B Ratio | 6.38 | 23.56 | -13.89 | -4.2 | -4.59 | |
| PTB ratio | 6.38 | 23.56 | -13.89 | -4.2 | -4.59 | |
| EV to sales | 62.69 | 5.86K | 34.58 | 30.51 | 13.73 | |
| Enterprise value over EBITDA | -2.71 | -3.29 | -5.18 | -3.71 | -30.08 | |
| EV to operating cash flow | -3.69 | -3.25 | -6.59 | -4.31 | 175.95 | |
| EV to free cash flow | -3.63 | -3.19 | -5.47 | -4.02 | 232.25 | |
| Earnings yield | -0.13 | -0.21 | -0.13 | -0.17 | -0.07 | |
| Free cash flow yield | -0.08 | -0.12 | -0.09 | -0.12 | 0.01 | |
| Debt to equity | 0.12 | 0.45 | -0.23 | -0.08 | -2.66 | |
| Debt to assets | 0.03 | 0.03 | 0.03 | 0.03 | 1.24 | |
| Net debt to EBITDA | 6.16 | 5.65 | 4.98 | 3.93 | -4.86 | |
| Current ratio | 8.34 | 8.54 | 6.85 | 5.28 | 4.42 | |
| Interest coverage | -3.95 | -3.51 | -3.17 | 2.69 | -1.28 | |
| Income quality | 0.58 | 0.78 | 0.59 | 0.66 | -0.1 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 9.6 | 789.5 | 3.07 | 3.07 | 0.46 | |
| Research and developement to revenue | 15.23 | 1.11K | 4.86 | 5.98 | 0.99 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.02 | 0.02 | 0.21 | 0.07 | -0.24 | |
| Capex to revenue | -0.28 | -28.75 | -1.08 | -0.52 | -0.02 | |
| Capex to depreciation | -4.14 | -7.67 | -68.56 | -27.81 | -6 | |
| Stock based compensation to revenue | 3.48 | 260.25 | 1.04 | 1.25 | 0.16 | |
| Graham number | 0.75 | 0.46 | 0.52 | 0.84 | 0.67 | |
| ROIC | -0.54 | -2.09 | 3.56 | 0.66 | -0.11 | |
| Return on tangible assets | -0.17 | -0.29 | -0.23 | -0.27 | -0.14 | |
| Graham Net | 0.13 | -0.01 | -0.14 | -0.28 | -0.33 | |
| Working capital | 42.48M | 37.58M | 30.83M | 24.98M | 23.31M | |
| Tangible asset value | 10.61M | 2.7M | -4.97M | -12.85M | -15.91M | |
| Net current asset value | 7.56M | 572K | -8.05M | -16.45M | -19.81M | |
| Invested capital | 0.12 | 0.45 | -0.23 | -0.08 | -2.66 | |
| Average receivables | 61.5K | 0 | 127.5K | 568.5K | 526K | |
| Average payables | 1.39M | 1.32M | 1.74M | 1.88M | 2.04M | |
| Average inventory | 523.5K | 0 | 271K | 829.5K | 558.5K | |
| Days sales outstanding | 0 | 0 | 22.54 | 92.41 | 2.41 | |
| Days payables outstanding | 463.24 | 9.56K | 796.9 | 1.18K | 9.92K | |
| Days of inventory on hand | 0 | 0 | 229.01 | 707.96 | 0 | |
| Receivables turnover | 0 | 0 | 3.99 | 0.97 | 37.32 | |
| Payables turnover | 0.19 | 0.01 | 0.11 | 0.08 | 0.01 | |
| Inventory turnover | 0 | 0 | 0.39 | 0.13 | 0 | |
| ROE | -0.81 | -4.86 | 1.83 | 0.72 | 0.3 | |
| Capex per share | 0 | 0 | -0.02 | -0.01 | 0 |
CLSD Frequently Asked Questions
What is Clearside Biomedical, Inc. stock symbol ?
Clearside Biomedical, Inc. is a US stock , located in Alpharetta of Ga and trading under the symbol CLSD
What is Clearside Biomedical, Inc. stock quote today ?
Clearside Biomedical, Inc. stock price is $1.27 today.
Is Clearside Biomedical, Inc. stock public?
Yes, Clearside Biomedical, Inc. is a publicly traded company.
Company Profile
- Volume Average 362.29K
- Market Capitalization 93.4M
- Employee 30
- CEO Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D.
- Headquarters Alpharetta,GA,US
- IPO Date 2016-06-02
-
Website
https://www.clearsidebio.com 
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
